May. 22, 2014 2:45 PM ET
http://seekingalpha.com/article/2233643-athersys-down-but-not-out-an-interview-with-ceo-van-bokkelen
Summary
•Shares Battered After Failure to Show Efficacy in Ulcerative Colitis (UC) Phase II.
•CEO Van Bokkelen Answers the Tough Questions Including: Why No Recent Insider Buying?.
•The Science Behind Multistem Stroke Therapy.
•Efficacy in Stroke Trial Unleashes Tremendous Value.
See above link for full article.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM